We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
(+2.1%)
Cap. Flow
-$39.8M
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$255M |
| 2 |
Boston Scientific
BSX
|
+$146M |
| 3 |
AbbVie
ABBV
|
+$121M |
| 4 |
AGN.PRA
Allergan plc
AGN.PRA
|
+$109M |
| 5 |
Puma Biotechnology
PBYI
|
+$103M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$207M |
| 2 |
Zimmer Biomet
ZBH
|
+$116M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$115M |
| 4 |
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
|
+$105M |
| 5 |
Stryker
SYK
|
+$87.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.53% |
| 2 | Financials | 0.24% |
| 3 | Technology | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ascendis Pharma A/S
ASND
$16.6B
| $25.6M | 0.21% |
1,448,991
| – | – |
|
77
Merck
MRK
$325B
| $23.6M | 0.2% |
434,920
+10,480
| +2% | +$588K |
|
|
CYNA
78
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $23.3M | 0.19% |
+1,140,325
| New | +$18.7M |
|
|
79
Zimmer Biomet
ZBH
$18.7B
| $23.2M | 0.19% |
218,669
-1,046,171
| -83% | -$116M |
|
80
Xencor
XNCR
$1.44B
| $22.9M | 0.19% |
1,044,615
| – | – |
|
|
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $21.4M | 0.18% |
680,500
-586,500
| -46% | -$17.3M |
|
82
Jazz Pharmaceuticals
JAZZ
$16.1B
| $20.2M | 0.17% |
115,000
| – | – |
|
|
83
CALL
AbbVie
ABBV
$472B
| $20.2M | 0.17% |
+300,000
| New | +$19.6M |
|
|
PVLA
84
Palvella Therapeutics
PVLA
$2B
| $20M | 0.17% |
+90,745
| New | +$20M |
|
|
CNXR
85
DELISTED
Connecture, Inc.
CNXR
| $18.4M | 0.15% |
1,740,000
| – | – |
|
86
Teva Pharmaceuticals
TEVA
$39.8B
| $18.1M | 0.15% |
307,000
-784,000
| -72% | -$48.4M |
|
|
87
Stryker
SYK
$135B
| $17.8M | 0.15% |
186,000
-927,000
| -83% | -$87.8M |
|
88
eHealth
EHTH
$42.2M
| $16.5M | 0.14% |
1,300,000
+1,026,900
| +376% | +$12.4M |
|
|
MRGE
89
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
| $15.9M | 0.13% |
3,308,400
-1,320,100
| -29% | -$6.32M |
|
|
ADXS
90
DELISTED
Advaxis Inc
ADXS
| $15.4M | 0.13% |
50,340
+21,667
| +76% | +$6.85M |
|
|
IMGN
91
DELISTED
Immunogen Inc
IMGN
| $14.8M | 0.12% |
+1,030,000
| New | +$11.3M |
|
92
Vertex Pharmaceuticals
VRTX
$124B
| $14.2M | 0.12% |
115,000
-20,000
| -15% | -$2.52M |
|
93
Insulet
PODD
$11.9B
| $14M | 0.12% |
453,000
-1,544,000
| -77% | -$45.5M |
|
|
SVA
94
DELISTED
Sinovac Biotech, Ltd
SVA
| $14M | 0.12% |
2,667,500
| – | – |
|
95
The Ensign Group
ENSG
$10.6B
| $12.6M | 0.11% |
+529,369
| New | +$11.6M |
|
|
CLLS
96
Cellectis
CLLS
$287M
| $12.6M | 0.11% |
350,000
+50,000
| +17% | +$1.76M |
|
|
AET
97
DELISTED
Aetna Inc
AET
| $12.2M | 0.1% |
96,000
+2,000
| +2% | +$228K |
|
98
Cardinal Health
CAH
$54.6B
| $12.2M | 0.1% |
146,000
-814,000
| -85% | -$71.9M |
|
99
MacroGenics
MGNX
$234M
| $12M | 0.1% |
+317,000
| New | +$10.4M |
|
|
SAGE
100
DELISTED
Sage Therapeutics
SAGE
| $10.9M | 0.09% |
150,000
-262,335
| -64% | -$16.9M |
|
Similar funds
HSA
NL
BPWM
LFG
JIM
CTC
PAMP
SGM
OrbiMed's Q2 2015 Portfolio in Review
As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.
- OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
- OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
- OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
- OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
- OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
- OrbiMed opened 29 new positions and closed 27 in Q2 2015.
- OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.
Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.